Robert Wessman, the Chairman of Lotus Pharmaceutical Co., Ltd (“Lotus” or “the Company”, Taiwan TWSE ticker: 1795), has announced the purchase of 300,000 shares, at an average NT$52.1 per share, in Lotus today. This acquisition has been made through investment company, Aztiq Lux Sarl.
Robert Wessman commented: